Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.0136 | 0 | 0.5 | |
Echinococcus multilocularis | acetylcholinesterase | 0.0803 | 1 | 1 |
Onchocerca volvulus | 0.0136 | 0 | 0.5 | |
Onchocerca volvulus | 0.0136 | 0 | 0.5 | |
Brugia malayi | Carboxylesterase family protein | 0.0803 | 1 | 1 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.0803 | 1 | 1 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.0803 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0803 | 1 | 1 |
Loa Loa (eye worm) | carboxylesterase | 0.0803 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0803 | 1 | 1 |
Mycobacterium ulcerans | carboxylesterase, LipT | 0.0136 | 0 | 0.5 |
Mycobacterium tuberculosis | POSSIBLE PARA-NITROBENZYL ESTERASE (FRAGMENT) | 0.0136 | 0 | 0.5 |
Onchocerca volvulus | 0.0136 | 0 | 0.5 | |
Trichomonas vaginalis | spcc417.12 protein, putative | 0.0136 | 0 | 0.5 |
Trichomonas vaginalis | carboxylesterase domain containing protein, putative | 0.0136 | 0 | 0.5 |
Mycobacterium tuberculosis | Carboxylesterase LipT | 0.0136 | 0 | 0.5 |
Echinococcus granulosus | carboxylesterase 5A | 0.0803 | 1 | 1 |
Echinococcus multilocularis | acetylcholinesterase | 0.0803 | 1 | 1 |
Mycobacterium tuberculosis | POSSIBLE PARA-NITROBENZYL ESTERASE (FRAGMENT) | 0.0136 | 0 | 0.5 |
Echinococcus granulosus | acetylcholinesterase | 0.0803 | 1 | 1 |
Echinococcus multilocularis | carboxylesterase 5A | 0.0803 | 1 | 1 |
Echinococcus granulosus | acetylcholinesterase | 0.0803 | 1 | 1 |
Onchocerca volvulus | 0.0136 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 1.9953 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 14.7157 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 25.1189 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 26.8545 uM | PUBCHEM_BIOASSAY: qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2288, AID2289, AID2598, AID411] | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PUBCHEM_BIOASSAY: qHTS assay for re-activators of p53 using a Luc reporter. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504709] | ChEMBL. | No reference |
Potency (functional) | 112.2018 uM | PubChem BioAssay. qHTS of PTHR Inhibitors: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.